MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies

Murielle Mimeault, Sonny L. Johansson, Shantibhusan Senapati, Navneet Momi, Subhankar Chakraborty, Surinder Kumar Batra

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The present study was undertaken to estimate the therapeutic benefit to down-regulate the MUC4 mucin for reversing chemoresistance of pancreatic cancer (PC) stem/progenitor cells and their progenies. The results have revealed that MUC4 mucin is overexpressed in CD133+ and CD133- pancreatic cells (PCs) detected in patient's adenocarcinoma tissues while no significant expression was seen in normal pancreatic tissues. The gain- and loss-of-function analyses have indicated that the overexpression of MUC4 in PC lines is associated with a higher resistance to the anti-proliferative, anti-invasive and apoptotic effects induced by gemcitabine. Importantly, the treatment of the MUC4-overexpressing CD18/HPAF-Src cells with gemcitabine resulted in an enrichment of the side population (SP) cells expressing CD133 while the total PC cells including non-SP cells detected in MUC4 knockdown CD18/HPAF-shMUC4 cells were responsive to the cytotoxic effects induced by gemcitabine. These data suggest that the MUC4 down-regulation may constitute a potential therapeutic strategy for improving the efficacy of gemcitabine to eradicate the total PC cell mass, and thereby preventing disease relapse.

Original languageEnglish (US)
Pages (from-to)69-84
Number of pages16
JournalCancer Letters
Volume295
Issue number1
DOIs
StatePublished - Sep 1 2010

Fingerprint

gemcitabine
Neoplastic Stem Cells
Pancreatic Neoplasms
Stem Cells
Down-Regulation
Mucins
Side-Population Cells
Adenocarcinoma
Therapeutics
Recurrence
Population

Keywords

  • Cancer therapies
  • Chemoresistance
  • Gemcitabine
  • MUC4 mucin
  • Pancreatic cancer
  • Pancreatic stem/progenitor cells
  • Side population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. / Mimeault, Murielle; Johansson, Sonny L.; Senapati, Shantibhusan; Momi, Navneet; Chakraborty, Subhankar; Batra, Surinder Kumar.

In: Cancer Letters, Vol. 295, No. 1, 01.09.2010, p. 69-84.

Research output: Contribution to journalArticle

Mimeault, Murielle ; Johansson, Sonny L. ; Senapati, Shantibhusan ; Momi, Navneet ; Chakraborty, Subhankar ; Batra, Surinder Kumar. / MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. In: Cancer Letters. 2010 ; Vol. 295, No. 1. pp. 69-84.
@article{8e1e3d671c91407597b4c13c98c72b01,
title = "MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies",
abstract = "The present study was undertaken to estimate the therapeutic benefit to down-regulate the MUC4 mucin for reversing chemoresistance of pancreatic cancer (PC) stem/progenitor cells and their progenies. The results have revealed that MUC4 mucin is overexpressed in CD133+ and CD133- pancreatic cells (PCs) detected in patient's adenocarcinoma tissues while no significant expression was seen in normal pancreatic tissues. The gain- and loss-of-function analyses have indicated that the overexpression of MUC4 in PC lines is associated with a higher resistance to the anti-proliferative, anti-invasive and apoptotic effects induced by gemcitabine. Importantly, the treatment of the MUC4-overexpressing CD18/HPAF-Src cells with gemcitabine resulted in an enrichment of the side population (SP) cells expressing CD133 while the total PC cells including non-SP cells detected in MUC4 knockdown CD18/HPAF-shMUC4 cells were responsive to the cytotoxic effects induced by gemcitabine. These data suggest that the MUC4 down-regulation may constitute a potential therapeutic strategy for improving the efficacy of gemcitabine to eradicate the total PC cell mass, and thereby preventing disease relapse.",
keywords = "Cancer therapies, Chemoresistance, Gemcitabine, MUC4 mucin, Pancreatic cancer, Pancreatic stem/progenitor cells, Side population",
author = "Murielle Mimeault and Johansson, {Sonny L.} and Shantibhusan Senapati and Navneet Momi and Subhankar Chakraborty and Batra, {Surinder Kumar}",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.canlet.2010.02.015",
language = "English (US)",
volume = "295",
pages = "69--84",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies

AU - Mimeault, Murielle

AU - Johansson, Sonny L.

AU - Senapati, Shantibhusan

AU - Momi, Navneet

AU - Chakraborty, Subhankar

AU - Batra, Surinder Kumar

PY - 2010/9/1

Y1 - 2010/9/1

N2 - The present study was undertaken to estimate the therapeutic benefit to down-regulate the MUC4 mucin for reversing chemoresistance of pancreatic cancer (PC) stem/progenitor cells and their progenies. The results have revealed that MUC4 mucin is overexpressed in CD133+ and CD133- pancreatic cells (PCs) detected in patient's adenocarcinoma tissues while no significant expression was seen in normal pancreatic tissues. The gain- and loss-of-function analyses have indicated that the overexpression of MUC4 in PC lines is associated with a higher resistance to the anti-proliferative, anti-invasive and apoptotic effects induced by gemcitabine. Importantly, the treatment of the MUC4-overexpressing CD18/HPAF-Src cells with gemcitabine resulted in an enrichment of the side population (SP) cells expressing CD133 while the total PC cells including non-SP cells detected in MUC4 knockdown CD18/HPAF-shMUC4 cells were responsive to the cytotoxic effects induced by gemcitabine. These data suggest that the MUC4 down-regulation may constitute a potential therapeutic strategy for improving the efficacy of gemcitabine to eradicate the total PC cell mass, and thereby preventing disease relapse.

AB - The present study was undertaken to estimate the therapeutic benefit to down-regulate the MUC4 mucin for reversing chemoresistance of pancreatic cancer (PC) stem/progenitor cells and their progenies. The results have revealed that MUC4 mucin is overexpressed in CD133+ and CD133- pancreatic cells (PCs) detected in patient's adenocarcinoma tissues while no significant expression was seen in normal pancreatic tissues. The gain- and loss-of-function analyses have indicated that the overexpression of MUC4 in PC lines is associated with a higher resistance to the anti-proliferative, anti-invasive and apoptotic effects induced by gemcitabine. Importantly, the treatment of the MUC4-overexpressing CD18/HPAF-Src cells with gemcitabine resulted in an enrichment of the side population (SP) cells expressing CD133 while the total PC cells including non-SP cells detected in MUC4 knockdown CD18/HPAF-shMUC4 cells were responsive to the cytotoxic effects induced by gemcitabine. These data suggest that the MUC4 down-regulation may constitute a potential therapeutic strategy for improving the efficacy of gemcitabine to eradicate the total PC cell mass, and thereby preventing disease relapse.

KW - Cancer therapies

KW - Chemoresistance

KW - Gemcitabine

KW - MUC4 mucin

KW - Pancreatic cancer

KW - Pancreatic stem/progenitor cells

KW - Side population

UR - http://www.scopus.com/inward/record.url?scp=77950828177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950828177&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2010.02.015

DO - 10.1016/j.canlet.2010.02.015

M3 - Article

C2 - 20303649

AN - SCOPUS:77950828177

VL - 295

SP - 69

EP - 84

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -